Citi analyst Geoff Meacham raised the firm’s price target on Pfizer (PFE) to $27 from $26 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- BofA ups BridgeBio price target, cites exclusivity ‘disappointment’ for pullback
- Midday Fly By: OpenAI said to miss targets, Coca-Cola reports Q1 beat
- Pfizer Vyndamax settlement at lower end of expectations, says Morgan Stanley
- BridgeBio turns negative after Pfizer details tamidis settlement
- BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement